Researchers involved in an international multicenter study (CHAT) have reported that the addition of Xeloda® (capecitabine) to Herceptin® (trastuzumab) and Taxotere® (docetaxel) improves response rate and progression-free survival in women with advanced or metastatic HER2-positive breast cancer. However, Xeloda increased toxicities significantly. The details of this study were published early online in the Journal of Clinical Oncology on December 28, 2009.

This entry was posted on Monday, February 8th, 2010 at 10:36 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.